The Role of Nanomedicine in Benign Gynecologic Disorders
Molecules · 2024
DOI: 10.3390/molecules29092095 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, 2024. Verfasst von Bethlehem A Lulseged und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA. Hauptthemen laut MEDLINE: Nanomedicine, Nanoparticles, Genital Diseases, Female. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, National Institutes of Health Grants, National Institutes of Health.
Abstract (Originalsprache)
Nanomedicine has revolutionized drug delivery in the last two decades. Nanoparticles appear to be a promising drug delivery platform in the treatment of various gynecological disorders including uterine leiomyoma, endometriosis, polycystic ovarian syndrome (PCOS), and menopause. Nanoparticles are tiny (mean size < 1000 nm), biodegradable, biocompatible, non-toxic, safe, and relatively inexpensive materials commonly used in imaging and the drug delivery of various therapeutics, such as chemotherapeutics, small molecule inhibitors, immune mediators, protein peptides and non-coding RNA. We performed a literature review of published studies to examine the role of nanoparticles in treating uterine leiomyoma, endometriosis, PCOS, and menopause. In uterine leiomyoma, nanoparticles containing 2-methoxyestradiole and simvastatin, promising uterine fibroid treatments, have been effective in significantly inhibiting tumor growth compared to controls in in vivo mouse models with patient-derived leiomyoma xenografts. Nanoparticles have also shown efficacy in delivering magnetic hyperthermia to ablate endometriotic tissue. Moreover, nanoparticles can be used to deliver hormones and have shown efficacy as a mechanism for transdermal hormone replacement therapy in individuals with menopause. In this review, we aim to summarize research findings and report the efficacy of nanoparticles and nanotherapeutics in the treatment of various benign gynecologic conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
- Department of Population, Family, and Reproductive Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.
- Department of Gynecology and Obstetrics, Johns Hopkins University, 720 Rutland Ave, Baltimore, MD 21205, USA.
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
ORCID-Profile: Bethlehem A Lulseged, Rachel Michel, Eslam E Saad, Mostafa A Borahay
Förderung
- NICHD NIH HHS
- National Institutes of Health Grants
- National Institutes of Health
Zitieren
APA
Lulseged, B. A., Ramaiyer, M. S., Michel, R., Saad, E. E., Ozpolat, B., & Borahay, M. A. (2024). The Role of Nanomedicine in Benign Gynecologic Disorders. Molecules. https://doi.org/10.3390/molecules29092095
Vancouver
Lulseged BA, Ramaiyer MS, Michel R, Saad EE, Ozpolat B, Borahay MA. The Role of Nanomedicine in Benign Gynecologic Disorders. Molecules. 2024. doi:10.3390/molecules29092095
BibTeX
@article{Lulseged2024,
author = {Lulseged, Bethlehem A and Ramaiyer, Malini S and Michel, Rachel and Saad, Eslam E and Ozpolat, Bulent and Borahay, Mostafa A},
title = {The Role of Nanomedicine in Benign Gynecologic Disorders},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29092095}
}
EUVIMED